About Liquid Genomics
Liquid Genomics is a company based in Torrance (United States) founded in 2013 was acquired by NantHealth in February 2018. Liquid Genomics has raised $4.86 million across 3 funding rounds from investors including NantHealth. Liquid Genomics operates in a competitive market with competitors including GRAIL, Color, Earli, RainDance and NovellusDx, among others.
- Headquarter Torrance, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.86 M (USD)
in 3 rounds
-
Latest Funding Round
$1.63 M (USD), Series A
Jan 18, 2017
- Investors
-
Employee Count
Not available
-
Acquired by
NantHealth
(Feb 01, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Liquid Genomics
Liquid Genomics has successfully raised a total of $4.86M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1.63 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Liquid Genomics
Liquid Genomics has secured backing from 1 investor. Prominent investors backing the company include NantHealth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Bioinformatics platforms are provided for cancer treatment identification.
|
Locked | Locked | Locked |
Investor details for Liquid Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Liquid Genomics
Investment portfolio details for Liquid Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Liquid Genomics
Detailed financials for Liquid Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Liquid Genomics Comparisons
Peer comparison for Liquid Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Liquid Genomics
Liquid Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Earli, RainDance and NovellusDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Early cancer detection tests are developed using synthetic biomarkers.
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
|
| Locked | Locked | Locked |
Developer of technology for precision cancer diagnosis and therapies
|
|
| Locked | Locked | Locked |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
Detailed competitors of Liquid Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Liquid Genomics
Complete news archive for Liquid Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Liquid Genomics
Liquid Genomics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Liquid Genomics is headquartered in Torrance, United States. It is registered at Torrance, California, United States.
Liquid Genomics is a funded company, having raised a total of $4.86M across 3 funding rounds to date.
Liquid Genomics offers blood-based molecular diagnostics for cancer. Its flagship product analyzes bloods samples for circulating tumor DNA and RNA using PCR to monitor efficacy of chemotherapy treatments and risk of cancer recurrence. Current markers tested are variants of EGFR, ALK, KRAS, BRAF, NRAS, PD-L1, AR-V7 and ROS1.
Liquid Genomics has 1 investor. Key investors include NantHealth.